AstraZeneca’s $1.5 Billion AI Drug Deal Tests the Future of Medicine

AstraZeneca has agreed to pay $40 million upfront to U.S. biotechnology company Insitro to discover and develop treatments for difficult-to-treat liver and heart diseases using artificial intelligence, as pharmaceutical companies invest in technology to improve the efficiency of drug development.

Under the multi-year agreement, Insitro could receive up to about $1.46 billion in development and commercial milestone payments, as well as royalties of a single-digit percentage on future sales, the British drugmaker said on Thursday.

The collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, and cardiomyopathies, a group of conditions affecting the heart muscle. Both have posed challenges for researchers seeking to identify the biological mechanisms driving disease and develop effective treatments, AstraZeneca said.

Insitro will use its “Virtual Human” platform, which combines laboratory-grown cell models and machine learning, to identify causal disease biology and advance targets nominated by AstraZeneca to the development-candidate stage. AstraZeneca will then conduct and fund clinical trials.

The agreement reflects growing interest in AI as a tool for addressing longstanding challenges in pharmaceutical research, where developing a successful medicine can take 10 to 15 years and cost as much as $2.8 billion, according to industry estimates. An estimated 80% to 90% of drug candidates fail during clinical development, underscoring the financial risks involved in bringing treatments to market.

AI systems can analyse large biological datasets, identify patterns associated with disease and help researchers prioritise potential drug targets and compounds for laboratory testing. The technology could reduce the number of unsuccessful experiments, although its broader impact on clinical success rates and approved medicines remains uncertain.

A study published in Cancer Treatment Reviews in October identified 129 AI-enabled therapeutic candidates across 69 companies that had entered human clinical trials by March 1, 2026. Of those candidates, 72 had completed Phase 1 trials and 24 had completed Phase 2, while only five had entered or completed Phase 3, the final major stage before potential regulatory approval.

The findings highlight the gap between AI’s growing role in early-stage drug discovery and evidence that it can consistently deliver treatments that succeed in later-stage trials.

“Choosing the new targets that we want to put into our discovery pipeline is ⁠one of the hardest things we do across research and development,” Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, said.

“By the time we read about a new pathway or target (in major ⁠scientific journals), it is no longer novel. It’s in the public domain and we’re already a few steps too late. But when we identify these unique connections early and test them ⁠in cellular systems, we’re ahead of the game.”

Barr said combining AI tools with experienced scientists could allow AstraZeneca to test fewer molecules in laboratories, reduce guesswork and accelerate the search for effective medicines.

The pharmaceutical industry has been experimenting with computational approaches to drug discovery for decades, but advances in machine learning, biological data generation and computing power have expanded the range of tasks that AI can support. More recently, pharmaceutical companies have deployed AI in target identification, molecular design, clinical trial planning and regulatory documentation.

AstraZeneca has been among the major drugmakers exploring AI to improve research and development, as companies face pressure to replenish pipelines with new medicines while controlling the cost and time required to bring them to market. The company has also invested in partnerships with technology and biotechnology firms to strengthen its use of data-driven drug discovery.

Insitro, founded by Daphne Koller in 2018, combines machine learning with experimental biology to build models of human disease. Its approach seeks to link computational predictions with evidence from laboratory experiments rather than relying solely on algorithms trained on existing datasets.

The company has expanded its pharmaceutical partnerships in recent years. It recently broadened its collaboration with Bristol Myers Squibb to advance a wider portfolio of targets for amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease. It has also partnered with Eli Lilly to develop AI models that predict the pharmacological properties of small molecules in living organisms.

The latest agreement gives AstraZeneca access to Insitro’s platform while leaving the larger costs and risks of clinical development with the drugmaker. The potential $1.46 billion in milestone payments would depend on the programmes reaching specified development and commercial targets, rather than representing guaranteed revenue for Insitro.

Stay ahead of the Stories shaping our world. Subscribe to Impact Newswire and join our 
WhatsApp Channel for updates on global tech, business, and innovation—all in one place.

Dive deeper into the future with the Cause Effect 4.0 Podcast, where we explore the ideas, trends, and technologies driving the global AI conversation.

Got a story to share? Contact Us to reach a global audience with Impact Newswire.